INNOVENT BIO News

INNOVENT BIO: INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY''S PRODUCT REVENUE IN THE FIRST QUARTER OF 2024

Apr 30 17:00

INNOVENT BIO: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Apr 30 07:10

INNOVENT BIO: 2023 ANNUAL REPORT

Apr 29 22:36

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 8 16:35

INNOVENT BIO: CLARIFICATION ANNOUNCEMENT - GRANT OF RESTRICTED SHARES

Apr 3 21:37

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION AND GRANTED PRIORITY REVIEW DESIGNATION FOR SINTILIMAB COMBINATION WITH FRUQUINTINIB FOR THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER

Apr 2 12:25

INNOVENT BIO: GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO DIRECTORS AND GRANT OF RESTRICTED SHARES

Mar 24 18:28

INNOVENT BIO: PROPOSED ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY

Mar 20 21:41

INNOVENT BIO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

Mar 20 18:30

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 6 22:40

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SECOND NEW DRUG APPLICATION FOR TALETRECTINIB (ROS1 INHIBITOR)

Mar 5 07:30

INNOVENT BIO: DATE OF BOARD MEETING

Feb 29 18:09

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE PHASE 3 CLINICAL STUDY OF IBI311 MET THE PRIMARY ENDPOINT IN TREATING THYROID EYE DISEASE

Feb 20 07:30

INNOVENT BIO: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION

Feb 9 19:08

INNOVENT BIO: APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE

Feb 9 19:01

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE FIRST NEW DRUG APPLICATION FOR MAZDUTIDE FOR CHRONIC WEIGHT MANAGEMENT

Feb 7 16:30

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Feb 6 18:11

INNOVENT BIO: INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY''S PRODUCT REVENUE IN THE FOURTH QUARTER OF 2023

Feb 6 17:19

INNOVENT BIO: RETIREMENT OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER

Feb 5 16:30

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE FIRST PHASE 3 CLINICAL TRIAL OF MAZDUTIDE IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY MET THE PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Jan 9 07:30